Lee Su Jin, Le Khang Duy Ricky, Christie Michael, Dunne Benjamin, Herath Dishan, McCusker Mark
Department of General Surgical Specialties, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Department of Radiology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Radiol Case Rep. 2024 Jul 9;19(9):4029-4033. doi: 10.1016/j.radcr.2024.06.046. eCollection 2024 Sep.
Pseudoprogression of malignancy in patients treated with systemic immunotherapy is a well- recognised phenomenon and has also been seen in patients treated with combined chemoimmunotherapy. Neoadjuvant chemoimmunotherapy prior to surgery is a relatively new treatment strategy for the management of many malignancies. We report the case of a patient who was suspected to have primary lung squamous cell carcinoma progression following neoadjuvant chemoimmunotherapy. Tissue histopathology from biopsies demonstrated granulomatous sarcoid-like inflammation rather than progression or metastatic disease. The patient proceeded to have successful surgical clearance of residual tumour. Significantly, failure to suspect granulomatous reactions and pseudoprogression has profound influence on the trajectory of patient care, such as, the potential for patients to miss out on curative surgery. In this case report and review of the literature, we evaluate the role of pseudoprogression and the need for radiologists to be aware of this phenomenon so that they do not mistakenly report new metastases and derail the treatment paradigm for patients with curable malignant conditions.
接受全身免疫治疗的患者中恶性肿瘤的假性进展是一种公认的现象,在接受联合化疗免疫治疗的患者中也有出现。术前新辅助化疗免疫治疗是许多恶性肿瘤治疗的一种相对较新的策略。我们报告了一例患者,其在新辅助化疗免疫治疗后被怀疑原发性肺鳞状细胞癌进展。活检组织病理学显示为肉芽肿性结节病样炎症,而非进展或转移性疾病。该患者随后成功进行了残余肿瘤的手术清除。值得注意的是,未能怀疑肉芽肿反应和假性进展会对患者的治疗轨迹产生深远影响,例如患者可能错过根治性手术的机会。在本病例报告及文献综述中,我们评估了假性进展的作用以及放射科医生了解这一现象的必要性,以便他们不会错误地报告新的转移灶并扰乱可治愈恶性疾病患者的治疗模式。